AndreaBozzo/ceres-open-data-index huggingface dataset:
Expression of ionotropic glutamate receptors in the retina of the

Background
          The expression of retinal CaMKII is up-regulated in the retina of the rdta mouse in which rod photoreceptors are genetically ablated. As ionotropic glutamate receptors are known substrates of CAMKII, this study set out to determine if the protein levels of ionotropic glutamate receptors in the rdta mouse retina are also affected.
        
        
          Results
          The NMDA receptor subunits (NR1, NR2A/B) and the GluR1; AMPA receptor subunit (GluR1) were examined in immunolabeled western blots. The results demonstrate that the amounts of NR1 and NR2A/B receptor subunits are significantly increased in crude synaptic membrane fractions isolated from retinae of the rdta mice when compared to their normal, littermate controls. The GluR1 receptor subunit and its phosphorylation are simultaneously increased in retinae of the rdta mice.
        
        
          Conclusions
          These data indicate that the NMDA receptors and AMPA (GluR1) receptors are altered in the retinae of rdta mice that lack rod photoreceptors. Because the rods are lost at an early stage in development, it is likely that these results are indicative of synaptic reorganization in the retina.
CFEOM1, the classic familial form of congenital fibrosis of the extraocular muscles, is genetically heterogeneous but does not result from mutations in

Background
          To learn about the molecular etiology of strabismus, we are studying the genetic basis of 'congenital fibrosis of the extraocular muscles' (CFEOM). These syndromes are characterized by congenital restrictive ophthalmoplegia affecting muscles in the oculomotor and trochlear nerve distribution. Individuals with the classic form of CFEOM are born with bilateral ptosis and infraducted globes. When all affected members of a family have classic CFEOM, we classify the family as a CFEOM1 pedigree. We have previously determined that a CFEOM1 gene maps to the FEOM1 locus on chromosome 12cen. We now identify additional pedigrees with CFEOM1 to determine if the disorder is genetically heterogeneous and, if so, if any affected members of CFEOM1 pedigrees or sporadic cases of classic CFEOM harbor mutations in ARIX, the CFEOM2 disease gene.
        
        
          Results
          Eleven new CFEOM1 pedigrees were identified. All demonstrated autosomal dominant inheritance, and nine were consistent with linkage to FEOM1. Two small CFEOM1 families were not linked to FEOM1, and both were consistent with linkage to FEOM3. We screened two CFEOM1 families consistent with linkage to FEOM2 and 5 sporadic individuals with classic CFEOM and did not detect ARIX mutations.
        
        
          Conclusions
          The phenotype of two small CFEOM1 families does not map to FEOM1, establishing genetic heterogeneity for this disorder. These two families may harbor mutations in the FEOM3 gene, as their phenotype is consistent with linkage to this locus. Thus far, we have not identified ARIX mutations in any affected members of CFEOM1 pedigrees or in any sporadic cases of classic CFEOM.
Publications Using SAMHSA DataMiami - Dade Div: Drug-Related Emergency Department Visits, 2004-2011 - All Visits

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits in the Dade County division of the Miami metropolitan area, covering 2004-2011. File includes all drug-related ED visits that are reportable to DAWN without regard for the reason for the visit or the specific drugs involved. It includes visits involving all forms of drug misuse or abuse plus visits resulting from adverse reaction, accidental ingestion, suicide attempts, and visits where patients were seeking detoxification services. These estimates are useful for looking at overall levels of drug involvement in ED visits.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Compound 527110: 1-Butanaine, 3-methyl, N-(2-propenyl)

Chemical compound data from PubChem database. IUPAC Name: 3-methyl-N-prop-2-enylbutan-1-amine. Molecular Formula: C8H17N. Molecular Weight: 127.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526395: 2,3,7-Tribromo,1-chloro-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 2,3,7-tribromo-1-chlorodibenzo-p-dioxin. Molecular Formula: C12H4Br3ClO2. Molecular Weight: 455.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
National Survey of Substance Abuse Treatment Services: State Profiles 2014

The 2014 National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. The N-SSATS, conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA), is designed to collect data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse facilities (both public and private) throughout the 50 states, the District of Columbia, and other U.S. jurisdictions.
Compound 528211: Benzoic acid, 2-hydroxy-4-methoxy, DTBS

Chemical compound data from PubChem database. IUPAC Name: 2,2-ditert-butyl-7-methoxy-1,3,2-benzodioxasilin-4-one. Molecular Formula: C16H24O4Si. Molecular Weight: 308.44. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528688: Benzene, 1-ethyl-2,3,4,5-tetramethyl

Chemical compound data from PubChem database. IUPAC Name: 1-ethyl-2,3,4,5-tetramethylbenzene. Molecular Formula: C12H18. Molecular Weight: 162.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400279-T1: [Translated] USE OF SULFATED POLYSACCHARIDES FOR THE TREATMENT OF THROMBOSIS

The invention concerns the use of a sulphated polysaccharide capable of being obtained by radical depolymerization of a raw fucan derived from Pheophyceae, said polysaccharide having a molar mass not more than 10,000 g/mol, to obtain a medicine for preventing or treating vascular thrombosis, in particular venous thrombosis, arterial thrombosis and arterial restenosis.
Short-term LDL cholesterol-lowering efficacy of plant stanol esters

Background
          The short-term cholesterol-lowering efficacy of plant stanol esters has been open to debate, and the data from different clinical studies with hypercholesterolemic subjects are variable, partly due to lack of systematic studies. Therefore, we investigated the time in days needed to obtain the full cholesterol-lowering effect of stanol esters in hypercholesterolemic subjects.
        
        
          Methods
          Eleven mildly to moderately hypercholesterolemic subjects consumed stanol ester margarine (2.0 g/day of stanols) as a part of their habitual diet for 14 days and the changes in serum lipid values were measured three times at 4, 8 and 15 days after the initiation of test margarine consumption (0 day). The returning of serum lipid concentrations to baseline was measured two times after 2 or 3 days and after 7 days of the end of the test margarine consumption.
        
        
          Results
          Serum LDL cholesterol concentrations were reduced from 0 day (4.51 ± 0.66 mmol/l) by 3.5% (P = ns), 9.9% (p < 0.05) and 10.2% (P < 0.05) at 4, 8 and 15 days, respectively. Serum campesterol/total cholesterol ratio, an indirect marker of intestinal cholesterol absorption, was significantly reduced on day 4 already. After ending the stanol ester use serum cholesterol concentrations began to return rapidly and after 7 days serum LDL cholesterol was 5.3% less than the initial value (P = ns).
        
        
          Conclusion
          The specific effect of plant stanol esters on serum LDL cholesterol can fully be obtained within 1–2 weeks of the use of plant stanol ester-enriched margarine.
Association of MHC and rheumatoid arthritis:HLA polymorphisms in phenotypic variants of rheumatoid arthritis

Genes in the human leukocyte antigen (HLA) region remain the most powerful disease risk genes in rheumatoid arthritis (RA). Several allelic variants of HLA-DRB1 genes have been associated with RA, supporting a role for T-cell receptor-HLA-antigen interactions in the pathologic process. Disease-associated HLA-DRB1 alleles are similar but not identical and certain allelic variants are preferentially enriched in patient populations with defined clinical characteristics. Also, a gene dosing effect of HLA-DRB1 alleles has been suggested by the accumulation of patients with two RA-associated alleles, especially in patient subsets with a severe disease course. Therefore, polymorphisms in HLA genes are being explored as tools to dissect the clinical heterogeneity of the rheumatoid syndrome. Besides HLA polymorphisms, other risk genes will be helpful in defining genotypic profiles correlating with disease phenotypes. One such phenotype is the type of synovial lesion generated by the patient. HLA genes in conjunction with other genetic determinants may predispose patients to a certain pathway of synovial inflammation. Also, patients may or may not develop extraarticular manifestations, which are critical in determining morbidity and mortality. HLA genes, complemented by other RA risk genes, are likely involved in shaping the T-cell repertoire, including the emergence of an unusual T-cell population characterized by the potential of vascular injury, such as seen in extraarticular RA.
Patent AT-E401369-T1: [Translated] ACCELERATED UV CURING

The invention relates to the use of an infrared absorber for accelerating the UV curing of a mass to be cured. The infrared absorber is preferably selected from ATO, ITO, ZnO, LaB6 and a mixture of said substances. A casting resin is preferably used as the mass to be cured, in particular a resin based on an acrylic resin or an acrylate resin. The invention permits the production of laminated panes, in which the starting mass is applied between the panes and converted to form the laminate.
Therapeutic Living Program Facilities

<div>[<a href='https://files.hawaii.gov/dbedt/op/gis/data/Therapeutic_Living_Pgm_Facilities.pdf' target='_blank' rel='nofollow ugc noopener noreferrer'>Metadata</a>]  Locations of therapeutic living program facilities in the State of Hawaii as of November 2021. Source: Created by Hawaii Statewide GIS Program from data downloaded from Hawaii State Department of Health Office of Health Care Assurance (OHCA), November 2021. Note: March 2023 - 2 facilities were deleted at the request of the Department of Health. <br /></div><div><br /></div><div>For more information, please see metadata at <a href='https://files.hawaii.gov/dbedt/op/gis/data/Therapeutic_Living_Pgm_Facilities.pdf' target='_blank' rel='nofollow ugc noopener noreferrer'>https://files.hawaii.gov/dbedt/op/gis/data/Therapeutic_Living_Pgm_Facilities.pdf</a> or contact Hawaii Statewide GIS Program, Office of Planning, State of Hawaii; PO Box 2359, Honolulu, Hi. 96804; (808) 587-2846; email: <a href='mailto:gis@hawaii.gov' target='_blank' rel='nofollow ugc noopener noreferrer'>gis@hawaii.gov</a>; Website: <a href='https://planning.hawaii.gov/gis' target='_blank' rel='nofollow ugc noopener noreferrer'>https://planning.hawaii.gov/gis</a>. Source: State of Hawaii Dept. of Health, November 2021.</div>
Provider Network Data: 2023 Quarter 1

This Provider Network Data contains information on individual and institutional providers participating in health plan networks from January through March 2023. Plan network data is collected from Medicaid, Commercial, and Exchange plans on a quarterly basis by the Department of Health, including managed care plans, as well as PPO/EPO plans.

For more information, please visit: <a href=https://pndslookup.health.ny.gov>https://pndslookup.health.ny.gov</a>
Patent AT-E400513-T1: [Translated] BOX WITH BOTTLE HOLDERS

Chemical patent from PubChem database. Patent Number: AT-E400513-T1. Title: Method for Synthesizing Organic Compounds. Filing Date: 2013-08-24. Inventors: Chen, Wei, Kumar, Raj, Williams, Sarah. Abstract: A method for synthesizing organic compounds is disclosed, comprising reacting starting materials under specific conditions to yield the desired produc... IPC Classifications: C07D, C07F, A61K. This patent covers 28 claims related to 7 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
National Estimates of Drug-Related Emergency Department Visits, 2004-2011 - All Alcohol

Excel file with national estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011 for emergency department visits involving alcohol.  For adults aged 21 and older, the alcohol was found in combination with other drugs. For patients under the age of 21, the visit may involve alcohol alone or in combination with other drugs.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Compound 529453: Diheptyl propylphosphonate

Chemical compound data from PubChem database. IUPAC Name: 1-methyl-7-prop-1-en-2-yl-1,2,3,5,6,7,8,8a-octahydroazulene-4-carboxylic acid. Molecular Formula: C15H22O2. Molecular Weight: 234.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400140-T1: [Translated] DISPLAY DEVICE FOR RECEIVER SYSTEM WITH DATA MEMORY

Electrical apparatus for processing received digital data into audio and/or video formats for listening via speakers and/or viewing via a display screen connected to the apparatus. The apparatus includes a memory means in which said received data can be stored for subsequent selective access by the user of the apparatus. The apparatus is provided with a display panel (2) and the panel and/or the display screen includes a plurality of light sources (6) and the illumination or non-illumination of the light source is controlled to indicate the selected mode of operation of the memory so as to provide a visual indication of the same to the user, and, if active, the illumination or non illumination of the light sources (6) is determined by the particular active mode of the memory.
Acetaminophen

Acetaminophen is a prescription medication used to relieve pain and reduce fever. This intravenous solution, manufactured by Fresenius Kabi USA, contains 10 mg/mL of acetaminophen and is packaged in 100 mL bags for hospital use. It is approved under NDA204767 for intravenous administration. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E40131-T1: [Translated] NEW PYRIDIN-2-ETHERS RESPECTIVELY PYRIDIN-2THIOETHERS WITH A NITROGEN-CONTAINING CYCLOALIPHATIC RING AND THEIR SULFORIDES, SULFONES AND PYRIDIN-N-OXIDES.

There are disclosed pyridine-2-ethers and pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring corresponding to the formula    <IMAGE>  I  the pyridine-N-oxides and/or amine oxides thereof and the pharmaceutically acceptable salts thereof. The compounds show analgesic activity.
How many replicates of arrays are required to detect gene expression changes in microarray experiments? A mixture model approach

Background
          It has been recognized that replicates of arrays (or spots) may be necessary for reliably detecting differentially expressed genes in microarray experiments. However, the often-asked question of how many replicates are required has barely been addressed in the literature. In general, the answer depends on several factors: a given magnitude of expression change, a desired statistical power (that is, probability) to detect it, a specified Type I error rate, and the statistical method being used to detect the change. Here, we discuss how to calculate the number of replicates in the context of applying a nonparametric statistical method, the normal mixture model approach, to detect changes in gene expression.
        
        
          Results
          The methodology is applied to a data set containing expression levels of 1,176 genes in rats with and without pneumococcal middle-ear infection. We illustrate how to calculate the power functions for 2, 4, 6 and 8 replicates.
        
        
          Conclusions
          The proposed method is potentially useful in designing microarray experiments to discover differentially expressed genes. The same idea can be applied to other statistical methods.
Provider Network Data: 2024 Quarter 2

This Provider Network Data contains information on individual and institutional providers participating in health plan networks from April through June 2024. Plan network data is collected from Medicaid, Commercial, and Exchange plans on a quarterly basis by the Department of Health, including managed care plans, as well as PPO/EPO plans.

For more information, please visit: <a href=https://pndslookup.health.ny.gov>https://pndslookup.health.ny.gov</a>
Compound 530631: Valeric acid, hex-4-yn-3-yl ester

Chemical compound data from PubChem database. IUPAC Name: hex-4-yn-3-yl pentanoate. Molecular Formula: C11H18O2. Molecular Weight: 182.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525717: p-Methylbenzylidene-(4-bromophenyl)-amine

Chemical compound data from PubChem database. IUPAC Name: N-(4-bromophenyl)-1-(4-methylphenyl)methanimine. Molecular Formula: C14H12BrN. Molecular Weight: 274.15. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530752: o-Methoxybenzoic acid, 3,5-difluorophenyl ester

Chemical compound data from PubChem database. IUPAC Name: (3,5-difluorophenyl) 2-methoxybenzoate. Molecular Formula: C14H10F2O3. Molecular Weight: 264.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2013 NSDUH Dependence, Abuse, and Treatment Tables (Standard Errors and P Values) - 5.1 to 5.56

These detailed tables present standard errors for totals and prevalence estimates of substance dependence/abuse and treatment need/receipt from the 2013 National Survey on Drug Use and Health (NSDUH). Substances examined include illicit drugs, marijuana, cocaine, heroin, hallucinogens, inhalants, and the nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, and sedatives, and alcohol.Standard errors are provided by age group, gender, race/ethnicity, education level, employment status, and geographic area. Standard errors are provided for both 2013 and 02012.
Compound 528209: Benzoic acid, 2-hydroxy-3-methyl-6-(1-methylethyl), DTBS

Chemical compound data from PubChem database. IUPAC Name: 2,2-ditert-butyl-8-methyl-5-propan-2-yl-1,3,2-benzodioxasilin-4-one. Molecular Formula: C19H30O3Si. Molecular Weight: 334.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Clinical review: Use of vancomycin in haemodialysis patients

Following intravenous administration, vancomycin is poorly metabolized and is mainly excreted unchanged in urine. Total body clearance is thus dependent on the kidney, and is correlated with glomerular filtration rate and creatinine clearance. Accumulation of vancomycin in patients with renal insufficiency may therefore occur, and this may lead to toxic side effects if dosage is not modified according to the degree of renal failure. Furthermore, vancomycin easily diffuses through dialysis membranes. The aim of the present review is to establish guidelines for handling this drug in such patients. We indicate how and when plasma concentrations of vancomycin should be determined in dialysis patients.
Compound 525058: N-methoxy-10,13-dimethyl-3,11-bis(trimethylsilyloxy)-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-imine

Chemical compound data from PubChem database. IUPAC Name: N-methoxy-10,13-dimethyl-3,11-bis(trimethylsilyloxy)-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-imine. Molecular Formula: C26H49NO3Si2. Molecular Weight: 479.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400568-T1: [Translated] SUBSTITUTED 4-(4-PIPERIDINE-YL-PIPERAZINE-1-YL)-AZEPAN DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS

The invention concerns substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives having neurokinin antagonistic activity, in particular NK~antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment of pain, emesis, anxiety, depression and IBS.
Compound 530153: Benzoic acid, 4-[(trimethylsilyl)amino]-, trimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 4-(trimethylsilylamino)benzoate. Molecular Formula: C13H23NO2Si2. Molecular Weight: 281.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530484: 5-Chlorovaleric acid, 4-hexadecyl ester

Chemical compound data from PubChem database. IUPAC Name: hexadecan-4-yl 5-chloropentanoate. Molecular Formula: C21H41ClO2. Molecular Weight: 361.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526026: 3,7,17-Trihydroxy-5-androstene, tris-TMS

Chemical compound data from PubChem database. IUPAC Name: [10,13-dimethyl-3,7-bis(trimethylsilyloxy)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]oxy-trimethylsilane. Molecular Formula: C28H54O3Si3. Molecular Weight: 523.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.